CNR2 and Parkinson disease: Preclinical studies have shown that the non-selective CB1/CB2 agonists WIN-55,212-2 and HU-210 improved PD-associated deficits in motor function [10,11,12] and increased the survival of SNc dopamine neurons in multiple PD models, including the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model [10,13,14].